Abstract
Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are prescribed to slow the progression of kidney disease in patients with Alport syndrome. In a recent publication by Yamamura et al. the authors showed an association of ACEi or ARB treatment with delay in ESKD, even for those patients with severe, truncating mutations. Despite these encouraging findings, there remain a number of clinical questions about the use of ACEi and ARBs in Alport syndrome.
Original language | English (US) |
---|---|
Pages (from-to) | 1400-1402 |
Number of pages | 3 |
Journal | Kidney international |
Volume | 98 |
Issue number | 6 |
DOIs |
|
State | Published - Dec 2020 |
Bibliographical note
Funding Information:MNR receives research funding from Advicenne, Reata, Retrophin, Sanofi, and Genentech.
Publisher Copyright:
© 2020 International Society of Nephrology
PubMed: MeSH publication types
- Journal Article
- Comment